The quadrivalent meningococcal vaccine MenQuadfi has landed in Korea.

The Ministry of Food and Drug Safety granted marketing authorization for Sanofi's invasive meningococcal disease (serogroups A, C, Y, W) vaccine, MenQuadfi (MenACYW-TT) on the 6th.

MenQuadfi is a fully liquid quadrivalent meningococcal vaccine that protects against meningococcal serogroups A, C, W, and Y. It was approved as a single-dose vaccine for persons aged 2 to 55 years. MenQuadfi is administered intramuscularily as a single 0.5ml into the deltoid region or anterolateral thigh depending on the recipient's age and muscle mass.

When evaluating immunogenicity and safety with other existing meningococ